2 weeks Ago By ABMN Staff
Canada Pension Plan Investment Board purchased a new stake in Pacira BioSciences, Inc. ( NASDAQ:PCRX – Free Report ) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 4,900 shares of the company’s stock, valued at approximately $140,000.
Several other large investors have also modified their holdings of the business. Texas Permanent School Fund Corp raised its holdings in shares of Pacira BioSciences by 1.4% in the 1st quarter.
Texas Permanent School Fund Corp now owns 40,642 shares of the company’s stock valued at $1,188,000 after purchasing an additional 543 shares in the last quarter. Duality Advisers LP raised its holdings in shares of Pacira BioSciences by 1.8% in the 1st quarter.
Duality Advisers LP now owns 34,784 shares of the company’s stock valued at $1,016,000 after purchasing an additional 605 shares in the last quarter. Inspire Investing LLC raised its holdings in shares of Pacira BioSciences by 5.9% in the 1st quarter.
Inspire Investing LLC now owns 12,131 shares of the company’s stock valued at $354,000 after purchasing an additional 675 shares in the last quarter. ICA Group Wealth Management LLC bought a new stake in shares of Pacira BioSciences in the 4th quarter valued at about $30,000. Finally, ProShare Advisors LLC grew its position in shares of Pacira BioSciences by 8.
0% in the 1st quarter. ProShare Advisors LLC now owns 12,461 shares of the company’s stock worth $364,000 after buying an additional 924 shares during the last quarter. Institutional investors own 99.
73% of the company’s stock. Pacira BioSciences Stock Up 1.5 % NASDAQ:PCRX opened at $14.
54 on Friday. The company has a market cap of $670.73 million, a PE ratio of 10.
17 and a beta of 0.84. Pacira BioSciences, Inc.
has a twelve month low of $11.16 and a twelve month high of $35.95.
The company has a current ratio of 6.82, a quick ratio of 5.70 and a debt-to-equity ratio of 0.
67. The company’s 50 day moving average is $15.84 and its two-hundred day moving average is $23.
46. Insider Activity In other Pacira BioSciences news, CEO Frank D. Lee acquired 8,264 shares of the company’s stock in a transaction dated Monday, August 12th.
The shares were acquired at an average cost of $12.10 per share, with a total value of $99,994.40.
Following the acquisition, the chief executive officer now directly owns 107,784 shares of the company’s stock, valued at $1,304,186.40. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website .
In other news, insider Jonathan Slonin sold 2,836 shares of the company’s stock in a transaction on Tuesday, July 2nd. The shares were sold at an average price of $28.25, for a total value of $80,117.
00. Following the sale, the insider now directly owns 95,557 shares of the company’s stock, valued at approximately $2,699,485.25.
The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink . Also, CEO Frank D. Lee acquired 8,264 shares of the company’s stock in a transaction dated Monday, August 12th.
The stock was acquired at an average cost of $12.10 per share, for a total transaction of $99,994.40.
Following the completion of the acquisition, the chief executive officer now directly owns 107,784 shares in the company, valued at $1,304,186.40. The disclosure for this purchase can be found here .
In the last ninety days, insiders have acquired 11,176 shares of company stock valued at $136,240 and have sold 4,281 shares valued at $105,494. Insiders own 6.40% of the company’s stock.
Analyst Upgrades and Downgrades A number of brokerages have recently issued reports on PCRX. Truist Financial downgraded shares of Pacira BioSciences from a “buy” rating to a “sell” rating and cut their price objective for the stock from $30.00 to $8.
00 in a research report on Tuesday, August 13th. JPMorgan Chase & Co. reaffirmed an “underweight” rating and issued a $10.
00 price objective (down previously from $45.00) on shares of Pacira BioSciences in a research report on Monday, August 12th. HC Wainwright cut their price objective on shares of Pacira BioSciences from $57.
00 to $39.00 and set a “buy” rating on the stock in a research report on Monday, August 12th. Royal Bank of Canada downgraded shares of Pacira BioSciences from an “outperform” rating to a “sector perform” rating and cut their price objective for the stock from $37.
00 to $14.00 in a research report on Monday, August 12th. Finally, StockNews.
com downgraded shares of Pacira BioSciences from a “strong-buy” rating to a “buy” rating in a research report on Monday, August 12th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, Pacira BioSciences has a consensus rating of “Hold” and a consensus price target of $24.
10. Read Our Latest Analysis on Pacira BioSciences About Pacira BioSciences ( Free Report ) Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.
Further Reading Receive News & Ratings for Pacira BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira BioSciences and related companies with MarketBeat.com's FREE daily email newsletter ..
